Clinical trial
A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects
NCT02891837 is registered in ClinicalTrials.gov with Asklepion Pharmaceuticals, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects
- Lead sponsor
- Asklepion Pharmaceuticals, LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- July 31, 2019
- Enrollment
- 189 (actual)
- Sites
- 29
Conditions
As the registry lists them; a condition with its own page is linked.